ImCheck Therapeutics Email Format
Biotechnology ResearchProvence-alpes-côte D'azur, France11-50 Employees
ImCheck Therapeutics is a biotechnology company based in Marseille, France, focused on developing antibody-based immunotherapies that target butyrophilins, a recently described family of immunomodulatory proteins. The organization operates with a compact, specialized team. Its core work lies in advancing immuno-oncology therapies. Its lead program ICT01 is a monoclonal antibody evaluated in acute myeloid leukemia and has received EMA Orphan Drug Designation. The company has shared interim results from AML trials at major oncology conferences, including ASCO 2025 and ASH 2024. Recent reports indicate Ipsen Group has acquired ImCheck Therapeutics.